Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601)
Atsushi Nakamura(Sendai Kousei Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Daisuke Jingu, Aya Suzuki(Tokyo Medical and Dental University), Hisashi Tanaka(Hirosaki University), Tōru Yamada(Tohoku University), Toshiyuki Harada(Hokkaido hospital), Sumito Inoue(Yamagata University), Taku Nakagawa(Saint John's Health Center), Ryota Saito(Tohoku University)
Cited by 6
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695